TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05381896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Scoliosis Exercise Program
Description: Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Scoliosis Exercise Program
Description: Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
Study: NCT05660642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-003
Description: Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-003
Description: Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Study: NCT04813120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)
Description: For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)
Description: During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)
Description: For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional MT using a mirror box
Description: During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
Study: NCT06414031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT05652309

Intervention type: PROCEDURE
Intervention: spinal block and obturator nerve block
Description: spinal block and obturator nerve block

Intervention type: PROCEDURE
Intervention: spinal block and obturator nerve block
Description: spinal block and obturator nerve block
Study: NCT06223074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV Methylprednisolone administration
Description: Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Methylprednisolone (MT)
Description: Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
Study: NCT05883683

Intervention type: OTHER
Intervention: Molecular Profiling & drug testing in tumor organoids and PDXs
Description: Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
Study: NCT05288478

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dentoxol mouthrinse dosages
Description: Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dentoxol mouthrinse dosages
Description: Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dentoxol mouthrinse dosages
Description: Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dentoxol mouthrinse dosages
Description: Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
Study: NCT06302478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5E program
Description: Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission
Study: NCT05616221

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo administered via inhalation
Study: NCT05603104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine Nasal Product
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate acid
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate acid
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: See arm description
Study: NCT05884255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Description: Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-acting Octreotide.
Description: High-dose long-acting Octreotide.
Study: NCT05496673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pastorex Latex Agglutination Test
Description: Rapid diagnosis of bacterial meningitis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biofire PCR for meningitis
Description: Rapid diagnosis of multiple forms of meningitis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immy CrAg Lateral Flow Assay
Description: Rapid diagnosis of cryptococcal meningitis
Study: NCT04863157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivor-SHIP
Description: Parent/guardian education about healthy sleep practices to improve their child's sleep health.
Study: NCT05175027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypochlorous acid
Description: Randomize

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypochlorous acid
Description: Randomize
Study: NCT05052658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial block placement
Description: The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuraxial block placement
Description: The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
Study: NCT05515107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope size 1 Miller blade
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Videolaryngoscope size 1 Miller blade
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
Study: NCT05698498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guaranteed Income
Description: Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public Benefits Information Session
Description: All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Public Benefits Information Session
Description: All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
Study: NCT04517500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based pulmonary rehabilitation program
Description: Subjects will wear an activity monitor while doing at home exercises using a computer tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Description: Subjects will wear an activity monitor while doing at home exercises using a computer tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful breathing module
Description: Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health coaching
Description: Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
Study: NCT05627297

Intervention type: OTHER
Intervention: CEUS and CEMRI
Description: contrast-enhanced ultrasound and contrast-enhanced MRI examination

Intervention type: OTHER
Intervention: CEUS and CEMRI
Description: contrast-enhanced ultrasound and contrast-enhanced MRI examination
Study: NCT04316650

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood and saliva samples
Description: Blood and saliva samples
Study: NCT05842733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naldebain
Description: Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
Study: NCT05746052

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Punch insturment
Description: surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
Study: NCT05541640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline group
Description: normal saline infusion at the start of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine group
Description: lidocaine infusion at the start of surgery
Study: NCT05909969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvi-Fit app Training
Description: This group will receive Pelvic Floor Muscle Strengthening exercises through software application.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
Study: NCT05842733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SafeTynadol
Description: Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naldebain + SafeTynadol
Description: Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
Study: NCT06146985

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 20 mg Famitinib & 1200 mg Adebrelimab
Description: Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 20 mg Famitinib & 1200 mg Adebrelimab
Description: Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 20 mg Famitinib & 1200 mg Adebrelimab
Description: Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
Study: NCT06501313

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: Soft laser therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Soft laser therapy
Study: NCT05497687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
Study: NCT05007132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab 20 milligram/ML
Description: Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil Hydrochloride
Description: Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipiracil Hydrochloride
Description: Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
Study: NCT04837495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right stellate ganglion block
Description: The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
Study: NCT05765591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy and aquatic exercises
Description: Information has already been included in arm/group descriptions
Study: NCT04724837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participants will receive zibotentan as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participants will receive zibotentan as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as per the arms they are randomized to.
Study: NCT05163639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive pairing of cortical and spinal stimulation
Description: Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive pairing of cortical and spinal stimulation
Description: Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
Study: NCT05490303

Intervention type: OTHER
Group type: OTHER
Intervention: recording of the probe position
Description: For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.